Phase 2
There are several recent announcements of German companies opening laboratories in the U.S.
Hookipa Biotech and Gilead inked a research collaboration deal to develop and commercialize therapeutics for hepatitis B (HBV) and HIV.
BioSpace takes a look at some notable programs that have been shuttered so far this year.
There’s plenty of news coming out of the American Society of Clinical Oncology (ASCO) Annual Meeting behind held in Chicago. Here’s a look at a few more of the top stories.
Bad news for Roche Holding AG. Two of its cancer drugs, Tecentriq and taselisib, have been shown to provide only modest protection from disease progression.
With the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ongoing, there are hundreds of newsworthy stories. Here is a few of our top picks so far.
It’s been a busy week for Nektar Therapeutics with the announcement of an NDA submission to the FDA for NKTR-181 and a non-exclusive, clinical collaboration deal with Syndax Pharmaceuticals.
Gilead Sciences and its development partner Galapagos NV announced positive data from its Phase II EQUATOR trial of filgotinib in psoriatic arthritis.
Madrigal Pharmaceuticals announced positive topline data from its Phase II clinical trial of MGL-3196 in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).
Shares of CRISPR Therapeutics plunged dramatically Wednesday after the U.S. Food and Drug Administration placed a clinical hold on a planned sickle cell disease treatment the company was in the process of developing with Vertex Pharmaceuticals.
PRESS RELEASES